Meta-analysis · people
Setmelanotide: injection-site reactions in 96% in pooled trials
Checked against the paper Meta-analysisPublished by PepVault
The takeaway
Injection-site reactions and skin darkening were the most common side effects seen with setmelanotide, followed by stomach effects such as nausea, vomiting and diarrhea.
- Kind
- Meta-analysis
- Studied in
- People
- Number studied
- 185
- Published
- 2026
- Journal
- Expert Opin Drug Saf
What they tested
The team set out to map the side effects linked to setmelanotide in obesity, using several sources of safety data together.
How the study was done
A systematic review and meta-analysis that pooled clinical trials with 185 people in total. The team also checked 228 reports in the US FDA Adverse Event Reporting System, a database of side-effect reports, and reviewed published case reports.

What they found
In the pooled trials, 96% of people had injection-site reactions (95% CI, the likely range: 89 to 100) and 62% had skin hyperpigmentation (95% CI: 43 to 78). Nausea occurred in 36%, vomiting in 26% and diarrhea in 21%. In the FDA database, the side effects reported more often than expected were skin hyperpigmentation, injection-site reactions, nausea, melanocytic nevus (moles) and ephelides (freckles), and the case reports matched these patterns. The authors call for careful patient monitoring and for safety follow-up lasting at least 1.5 years.
What it doesn’t show
The pooled rates show how often each side effect happened in people taking setmelanotide, not how much more often than without it, and they rest on only 185 people. Reports sent to a safety database flag possible signals but cannot show how common an effect is.
The paper
Sridharan and Sivaramakrishnan Adverse event profile of setmelanotide in obesity: an integrated assessment and systematic review using disproportionality analysis, case reports and meta-analysis. Expert Opin Drug Saf. 2026.
The compound
More studies on Setmelanotide
- Setmelanotide: 16.5% BMI drop at 52 weeks in hypothalamic obesityRandomized trial · people · 2026
- Setmelanotide: patients reported less hunger, more energy in TRANSCENDClinical trial · people · 2026
- Setmelanotide: mean BMI fell 18% at 52 weeks in ages 2-5 (VENTURE)Clinical trial · people · 2025
- Setmelanotide: 15% mean BMI drop at 16 weeks in hypothalamic obesityClinical trial · people · 2024
- Setmelanotide: quality of life rose after 52 weeks in Bardet-BiedlClinical trial · people · 2023
- Setmelanotide: 80% (POMC) and 45% (LEPR) lost at least 10% weightClinical trial · people · 2020
- Every study on Setmelanotide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.